Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2011

Open Access 01-12-2011 | Research

T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3

Authors: Jon G Quatromoni, Lilah F Morris, Timothy R Donahue, Yue Wang, William McBride, Talal Chatila, James S Economou

Published in: Journal of Hematology & Oncology | Issue 1/2011

Login to get access

Abstract

Regulatory T cells (Treg) that express the transcription factor Foxp3 are enriched within a broad range of murine and human solid tumors. The ontogeny of these Foxp3 Tregs - selective accumulation or proliferation of natural thymus-derived Treg (nTreg) or induced Treg (iTreg) converted in the periphery from naïve T cells - is not known. We used several strains of mice in which Foxp3 and EGFP are coordinately expressed to address this issue. We confirmed that Foxp3-positive CD4 T cells are enriched among tumor-infiltrating lymphocytes (TIL) and splenocytes (SPL) in B16 murine melanoma-bearing C57BL/6 Foxp3EGFP mice. OT-II Foxp3EGFP mice are essentially devoid of nTreg, having transgenic CD4 T cells that recognize a class II-restricted epitope derived from ovalbumin; Foxp3 expression could not be detected in TIL or SPL in these mice when implanted with ovalbumin-transfected B16 tumor (B16-OVA). Likewise, TIL isolated from B16 tumors implanted in Pmel-1 Foxp3EGFP mice, whose CD8 T cells recognize a class I-restricted gp100 epitope, were not induced to express Foxp3. All of these T cell populations - wild-type CD4, pmel CD8 and OTII CD4 - could be induced in vitro to express Foxp3 by engagement of their T cell receptor (TCR) and exposure to transforming growth factor β (TGFβ). B16 melanoma produces TGFβ and both pmel CD8 and OTII CD4 express TCR that should be engaged within B16 and B16-OVA respectively. Thus, CD8 and CD4 transgenic T cells in these animal models failed to undergo peripheral induction of Foxp3 in a tumor microenvironment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 2010, 127 (4): 759-67.PubMed Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 2010, 127 (4): 759-67.PubMed
3.
go back to reference Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003, 4 (4): 330-6.CrossRefPubMed Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003, 4 (4): 330-6.CrossRefPubMed
4.
go back to reference Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003, 299 (5609): 1057-61.CrossRefPubMed Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003, 299 (5609): 1057-61.CrossRefPubMed
6.
go back to reference Collison LW: Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009, 182 (10): 6121-8.PubMedCentralCrossRefPubMed Collison LW: Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009, 182 (10): 6121-8.PubMedCentralCrossRefPubMed
7.
go back to reference Yamagiwa S: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol. 2001, 166 (12): 7282-9.CrossRefPubMed Yamagiwa S: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol. 2001, 166 (12): 7282-9.CrossRefPubMed
8.
go back to reference Fantini MC: Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004, 172 (9): 5149-53.CrossRefPubMed Fantini MC: Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004, 172 (9): 5149-53.CrossRefPubMed
10.
go back to reference Myers L: Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol. 2005, 174 (12): 7625-32.CrossRefPubMed Myers L: Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol. 2005, 174 (12): 7625-32.CrossRefPubMed
11.
go back to reference Mayer CT: CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity. Eur J Immunol. 2011, 41 (3): 716-25.CrossRefPubMed Mayer CT: CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity. Eur J Immunol. 2011, 41 (3): 716-25.CrossRefPubMed
12.
go back to reference Smith TR, Kumar V: Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008, 29 (7): 337-42.CrossRefPubMed Smith TR, Kumar V: Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008, 29 (7): 337-42.CrossRefPubMed
13.
14.
go back to reference Liyanage UK: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002, 169 (5): 2756-61.CrossRefPubMed Liyanage UK: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002, 169 (5): 2756-61.CrossRefPubMed
15.
go back to reference Somasundaram R: Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002, 62 (18): 5267-72.PubMed Somasundaram R: Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002, 62 (18): 5267-72.PubMed
16.
go back to reference Ichihara F: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003, 9 (12): 4404-8.PubMed Ichihara F: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003, 9 (12): 4404-8.PubMed
17.
go back to reference Sasada T: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003, 98 (5): 1089-99.CrossRefPubMed Sasada T: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003, 98 (5): 1089-99.CrossRefPubMed
18.
go back to reference Ormandy LA: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65 (6): 2457-64.CrossRefPubMed Ormandy LA: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65 (6): 2457-64.CrossRefPubMed
19.
go back to reference Woo EY: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61 (12): 4766-72.PubMed Woo EY: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61 (12): 4766-72.PubMed
20.
go back to reference Viguier M: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004, 173 (2): 1444-53.CrossRefPubMed Viguier M: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004, 173 (2): 1444-53.CrossRefPubMed
21.
go back to reference Gray CP, Arosio P, Hersey P: Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res. 2003, 9 (7): 2551-9.PubMed Gray CP, Arosio P, Hersey P: Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res. 2003, 9 (7): 2551-9.PubMed
22.
go back to reference Gallimore AM, Simon AK: Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008, 27 (45): 5886-93.CrossRefPubMed Gallimore AM, Simon AK: Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008, 27 (45): 5886-93.CrossRefPubMed
24.
go back to reference Badoual C: Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006, 12 (2): 465-72.CrossRefPubMed Badoual C: Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006, 12 (2): 465-72.CrossRefPubMed
25.
go back to reference Curiel TJ: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10 (9): 942-9.CrossRefPubMed Curiel TJ: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10 (9): 942-9.CrossRefPubMed
26.
go back to reference Haribahi D: Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol. 2007, 178: 2961-72.CrossRef Haribahi D: Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol. 2007, 178: 2961-72.CrossRef
27.
go back to reference Vo DD: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009, 69: 8693-9.PubMedCentralCrossRefPubMed Vo DD: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009, 69: 8693-9.PubMedCentralCrossRefPubMed
28.
go back to reference Gobert M: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69: 2000-9.CrossRefPubMed Gobert M: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69: 2000-9.CrossRefPubMed
29.
go back to reference Lin W: Regulatory T cell development in the absence of functional Foxp3. Nat Immunol. 2007, 8: 359-68.CrossRefPubMed Lin W: Regulatory T cell development in the absence of functional Foxp3. Nat Immunol. 2007, 8: 359-68.CrossRefPubMed
30.
go back to reference Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003, 3 (3): 253-7.CrossRefPubMed Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003, 3 (3): 253-7.CrossRefPubMed
31.
go back to reference Chatila T: Molecular mechanisms of regulatory T cell development. J Clin Immunol. 2008, 28 (6): 625-30.CrossRefPubMed Chatila T: Molecular mechanisms of regulatory T cell development. J Clin Immunol. 2008, 28 (6): 625-30.CrossRefPubMed
32.
go back to reference Horwitz DA, Zheng SG, Gray JD: Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008, 29 (9): 429-35.CrossRefPubMed Horwitz DA, Zheng SG, Gray JD: Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008, 29 (9): 429-35.CrossRefPubMed
33.
go back to reference Selvaraj RK, Geiger TL: A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol. 2007, 179 (2): 11. following 1390.-CrossRef Selvaraj RK, Geiger TL: A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol. 2007, 179 (2): 11. following 1390.-CrossRef
34.
go back to reference Zheng SG: IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007, 178 (4): 2018-27.CrossRefPubMed Zheng SG: IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007, 178 (4): 2018-27.CrossRefPubMed
35.
go back to reference Peng Y: TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA. 2004, 101 (13): 4572-7.PubMedCentralCrossRefPubMed Peng Y: TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA. 2004, 101 (13): 4572-7.PubMedCentralCrossRefPubMed
36.
go back to reference Kim CH: Trafficking of FoxP3+ regulatory T cells: myths and facts. Arch Immunol Ther Exp (Warsz). 2007, 55 (3): 151-9.CrossRef Kim CH: Trafficking of FoxP3+ regulatory T cells: myths and facts. Arch Immunol Ther Exp (Warsz). 2007, 55 (3): 151-9.CrossRef
37.
go back to reference Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006, 97 (11): 1139-46.CrossRefPubMed Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006, 97 (11): 1139-46.CrossRefPubMed
38.
go back to reference Wei S: Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 2007, 67 (15): 7487-94.CrossRefPubMed Wei S: Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 2007, 67 (15): 7487-94.CrossRefPubMed
39.
go back to reference Kryczek I: CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005, 65 (2): 465-72.PubMed Kryczek I: CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005, 65 (2): 465-72.PubMed
40.
go back to reference Mizukami Y: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008, 122 (10): 2286-93.CrossRefPubMed Mizukami Y: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008, 122 (10): 2286-93.CrossRefPubMed
41.
go back to reference Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009, 30 (5): 636-45.CrossRefPubMed Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009, 30 (5): 636-45.CrossRefPubMed
42.
go back to reference Bettelli E: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441 (7090): 235-8.CrossRefPubMed Bettelli E: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441 (7090): 235-8.CrossRefPubMed
43.
44.
go back to reference Sharma S: Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005, 65 (12): 5211-20.CrossRefPubMed Sharma S: Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005, 65 (12): 5211-20.CrossRefPubMed
45.
go back to reference Curti A: Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007, 109 (7): 2871-7.PubMed Curti A: Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007, 109 (7): 2871-7.PubMed
46.
go back to reference You S: Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev. 2006, 212: 185-202.CrossRefPubMed You S: Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev. 2006, 212: 185-202.CrossRefPubMed
47.
go back to reference Moo-Young TA: Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother. 2009, 32 (1): 12-21.CrossRefPubMed Moo-Young TA: Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother. 2009, 32 (1): 12-21.CrossRefPubMed
48.
go back to reference Liyanage UK: Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006, 29 (4): 416-24.CrossRefPubMed Liyanage UK: Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006, 29 (4): 416-24.CrossRefPubMed
Metadata
Title
T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3
Authors
Jon G Quatromoni
Lilah F Morris
Timothy R Donahue
Yue Wang
William McBride
Talal Chatila
James S Economou
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2011
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-4-48

Other articles of this Issue 1/2011

Journal of Hematology & Oncology 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine